

MEMORANDUM OF UNDERSTANDING

Between

MUSCULAR DYSTROPHY PATIENTS' WELFARE SOCIETY

And

**INDIAN INSTITUTE OF SCIENCE EDUCATION AND
RESEARCH (IISER), KOLKATA**

WHEREAS

Co Investigator - Dr Sengupta is a very well known name in the field of Biological Science. He is a specialist in Cancer Biology, Bacterial interaction, Bioremediation.

WHEREAS

Co Investigator -Dr Ray is a very well known name in the field of Biological Science. He is a specialist in Molecular Biology, Translational Control, RNA Biology.

NOW THEREFORE:

Considering these legal and institutional relations, the successful implementation and operation of the Clinical Trial requires the partnership between the two (2) signatory institutions and the individual which this MoU shall facilitate. The parties therefore have entered into this Memorandum of Understanding (here-in-after referred to as "MoU") for the grant easement of the Clinical Trial.

ARTICLE I: Purpose

With the object of promoting their co-operation in CLINICAL STUDY and research, over DUCHENNE MUSCULAR DYSTROPHY in Institute of Child Health (ICH).

ARTICLE II: Forms of Co-operation

Within such fields as are mutually acceptable for the Parties, the following forms of co-operation, amongst others, may be pursued hereunder:

- Inclusion of Dr. Tapas Sengupta & Dr. Partha Sarothi Ray as the CO-PI in the study
- Exchange of ideas related to the study
- Use of the Biological Laboratory of the 2nd part

ARTICLE III: Specific Co-operation Projects

Specific co-operation projects, for instance within such fields as described in section 2 above, must be negotiated separately between the Parties and are in each specific case to be established in separate written agreements, stating the respective rights and obligations of the Parties. In case of any ambiguity or conflict of terms between the terms and conditions of this MoU and those of a separate agreement as mentioned above, the terms and conditions of such separate agreement shall prevail.

ARTICLE IV: Financial Arrangements

Both Parties understand that all financial arrangements required between the parties is confirmed (and mutually agreed. Both parties may seek financing of joint activities from internal and external sources available to them. The participation of the 2nd part in the Purpose mentioned in ARTICLE I is purely on voluntary and collaborative basis and no financial compensation is being accepted by the Co PIs. However, all recurring and capital expenses related to the usage of the Biological Laboratories of the Co-PIs or other facilities of the Institute, including the purchase of chemicals, reagents, laboratory equipment and consumables for the above-mentioned Purpose will be compensated by the 1st part.

ARTICLE V: Special Conditions


All the parties shall conform to all applicable laws and regulations and respect in all circumstances the basic principles governing the clinical trial.

ARTICLE XII: Commencement, Renewal, Termination

This MoU will be effective from the date of the last signature hereto and will remain in force for a time period of three (3) years, with a possibility for renewal at the end of the three-year-period, subject to the Parties' written agreement. Either Party may terminate this MoU by giving six (6) months' notice in writing to the other Party.

This MoU has been drawn up in two (2) original copies in the English language, each Party receiving one duly signed copy hereof.

Signature on behalf of MDPWS
MUSCULAR DYSTROPHY PATIENTS' WELFARE SOCIETY



President

Place: Kolkata

Date: 25.08.2019

Nirmalya Roy
President MDPWS

Signature on behalf of IISER:


Prof. Sourav Pal
निदेशक/Director
Place: Kolkata भारतीय विज्ञान शिक्षा एवं अनुसंधान संस्थान कोलकाता
Indian Institute of Science Education and Research Kol
(Under Ministry of HRD, Govt. of India)
मोहनपुर/Mohanpur-741246, पश्चिम बंगाल/West Be

Date: 17.09.2019

Dr. Sourav Pal
Director IISER